European Archives of Oto-Rhino-Laryngology

, Volume 264, Issue 7, pp 789–795

Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study

Head and Neck


The proliferative activity of the tumor cells and the expression of tumor-associated genes and sex steroid hormone receptors were investigated immunohistochemically in ten cases of carcinoma ex pleomorphic adenoma (Ca-ex-PA) of the salivary glands. These were analyzed in benign and malignant components separately, and then were compared with ten cases of the other malignant tumors [adenocarcinomas, not otherwise specified (ACN) and salivary duct carcinomas (SDC)] and ten cases of pleomorphic adenomas (PA). The results obtained in this study were as follows: (1) malignant component of Ca-ex-PA showed a higher incidence of PCNA and Ki67 than benign component of Ca-ex-PA. A significant difference between benign component of Ca-ex-PA and PA was not observed. (2) A significant difference in the incidence of p53, c-erbB-2, EGFR overexpression was observed only between malignant component of Ca-ex-PA and benign component of Ca-ex-PA. (3) The incidence of PCNA, Ki67, p53, c-erbB-2 overexpression in malignant component of Ca-ex-PA showed the highest data among the four groups. These results suggest that Ca-ex-PA acquired the particular biological behavior in contrast to the other salivary neoplasms in the long-standing process while PA undergoes malignant transformation.


Salivary gland tumor Carcinoma ex pleomorphic adenoma Immunohistochemistry c-erbB-2 Androgen receptor 


  1. 1.
    Eneroth CM (1964) Histological and clinical aspects of parotid tumours. Acta Otolaryngol Suppl 191:1–99Google Scholar
  2. 2.
    Eneroth CM, Blanck C, Jakobsson PA (1968) Carcinoma in pleomorphic adenoma of the parotid gland. Acta Otolaryngol 66:477–492PubMedGoogle Scholar
  3. 3.
    Evenson JW, Auclair P, Gnepp DR, El-Naggar AK (2005) World Health Organization classification tumours. Pathology and genetics of head and neck tumours, Chapter 5. IARC, LyonGoogle Scholar
  4. 4.
    LiVolsi VA, Perzin KH (1977) Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer 39:2209–2230PubMedCrossRefGoogle Scholar
  5. 5.
    Ellis GL, Auclair PL (1996) Atlas of tumor pathology, third series, fascicle 17. Tumors of the salivary glands. AFIP, Washington DC, pp 155–373Google Scholar
  6. 6.
    Spiro RH, Huvos AG, Strong EW (1977) Malignant mixed tumor of salivary origin: a clinicopathologic study of 146 cases. Cancer 39:388–396PubMedCrossRefGoogle Scholar
  7. 7.
    Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 110:172–176PubMedGoogle Scholar
  8. 8.
    Luna MA (2001) Salivary glands. In: Pilch BZ (ed) Head and neck surgical pathology. Lippincott Williams & Wilkins, Philadelphia, pp 248–349Google Scholar
  9. 9.
    Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRefGoogle Scholar
  10. 10.
    Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23:705–712PubMedCrossRefGoogle Scholar
  11. 11.
    Allison RT, Best T (1998) p53, PCNA and Ki-67 expression in oral squamous cell carcinomas: the vagaries of fixation and microwave enhancement of immunocytochemistry. J Oral Pathol Med 27:434–440PubMedCrossRefGoogle Scholar
  12. 12.
    Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM (1997) Expression and mutations of p53 in salivary gland tumours. J Oral Pathol Med 26:217–223PubMedCrossRefGoogle Scholar
  13. 13.
    Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F (1997) Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer 79:2314–2319PubMedCrossRefGoogle Scholar
  14. 14.
    Yamamoto Y, Kishimoto Y, Wistuba II, Virmani AK, Vuitch F, Gazdar AF, Albores-Saavedra J (1998) DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathol Int 48:265–272PubMedCrossRefGoogle Scholar
  15. 15.
    Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E (1995) p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75:2037–2044PubMedCrossRefGoogle Scholar
  16. 16.
    Freitas LL, Araujo VC, Martins MT, Chone C, Crespo A, Altemani A (2005) Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation. Int J Surg Pathol 13:337–342PubMedCrossRefGoogle Scholar
  17. 17.
    Ohtake S, Cheng J, Ida H, Suzuki M, Ohshiro K, Zhang W, Saku T (2002) Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J Oral Pathol Med 31:590–597PubMedCrossRefGoogle Scholar
  18. 18.
    Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, Ebihara S, Takeyama I (1992) Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102:923–927PubMedCrossRefGoogle Scholar
  19. 19.
    Kim YT, Kim JW, Lee JW (1998) c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. Cancer Lett 132:91–97PubMedCrossRefGoogle Scholar
  20. 20.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedCrossRefGoogle Scholar
  21. 21.
    Hellquist HB, Karlsson MG, Nilsson C (1994) Salivary duct carcinoma—a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 172:35–44PubMedCrossRefGoogle Scholar
  22. 22.
    Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC (1995) Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 56:914–918CrossRefGoogle Scholar
  23. 23.
    Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232PubMedGoogle Scholar
  24. 24.
    Yamada K, Iwai K, Okada Y, Mori M (1989) Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 415:523–531PubMedCrossRefGoogle Scholar
  25. 25.
    Seifert G, Caselitz J, Hamper K (1987) Receptors and proliferative markers in salivary gland tumors. J Tumor Marker Oncol 2:291–303Google Scholar
  26. 26.
    Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Ootsuki K, Terakado N, Matsumura T (1995) Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res 15:2623–2626PubMedGoogle Scholar
  27. 27.
    Nagao T, Sugano I, Ishida Y, Hasegawa M, Matsuzaki O, Konno A, Kondo Y, Nagao K (1998) Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Cancer 82:439–447PubMedCrossRefGoogle Scholar
  28. 28.
    Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRefGoogle Scholar
  29. 29.
    Jeannon JP, Soames JV, Bell H, Wilson JA (1999) Immunohistochemical detection of oestrogen and progesterone receptors in salivary tumours. Clin Otolaryngol Allied Sci 24:52–54PubMedCrossRefGoogle Scholar
  30. 30.
    Onitsuka T (1994) Sex hormones in papillary carcinoma of thyroid gland and pleomorphic adenoma of parotid gland. Acta Otolaryngol 114:218–222PubMedGoogle Scholar
  31. 31.
    Miller AS, Hartman GG, Chen SY, Edmonds PR, Brightman SA, Harwick RD (1994) Estrogen receptor assay in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin. An immunohistochemical study. Oral Surg Oral Med Oral Pathol 77:36–40PubMedCrossRefGoogle Scholar
  32. 32.
    Shick PC, Riordan GP, Foss RD (1995) Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80:440–444PubMedCrossRefGoogle Scholar
  33. 33.
    Lamey PJ, Leake RE, Cowan SK, Soutar DS, McGregor IA, McGregor FM (1987) Steroid hormone receptors in human salivary gland tumours. J Clin Pathol 40:532–534PubMedCrossRefGoogle Scholar
  34. 34.
    Nasser SM, Faquin WC, Dayal Y (2003) Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119(6):801–806PubMedCrossRefGoogle Scholar
  35. 35.
    Kapadia SB, Barnes L (1998) Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 11:1033–1038PubMedGoogle Scholar
  36. 36.
    Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24:579–586PubMedCrossRefGoogle Scholar
  37. 37.
    Hoang MP, Callender DL, Sola Gallego JJ, Huang Z, Sneige N, Luna MA, Batsakis JG, El-Naggar AK (2001) Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 19:865–871PubMedGoogle Scholar
  38. 38.
    Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M (2001) Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 93:344–350PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of OtolaryngologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations